D

Dynavax Technologies Corp

D
DVAX
USD
-0.29
(-2.3577%)
Market Closed
44,832.00
Volume
0.05
EPS
-
Div Yield
92.385
P/E
1,573,843,039.83
Market Cap
Today
-2.3577%
1 Week
1.307%
1 Month
11.565%
6 Months
2.039%
12 Months
-9.902%
Year To Date
-14.061%
All Time
0%

Title:
Dynavax Technologies Corp

Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Do you need help or have a question?